Jeong Eun Kim1, Yong Sang Hong1, Hwa Jung Kim2, Kyu-Pyo Kim1, Jae-Lyun Lee1, Seong Joon Park1, Seok-Byung Lim3, In Ja Park3, Chan Wook Kim3, Yong Sik Yoon3, Chang Sik Yu3, Jin Cheon Kim3, Kim Ji Hoon4, Tae Won Kim5. 1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 2. Department of Preventive Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 3. Department of Colorectal Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 4. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 5. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. twkimmd@amc.seoul.kr.
Abstract
BACKGROUND: Mismatch repair (MMR) status has been proposed, with some controversy, as a prognostic and predictive marker in stage II colon cancer. The aim of this study was to evaluate the association between MMR and survival in stage II colon cancer. METHODS: A total of 860 patients with curatively resected stage II colon cancer were selected for inclusion between January 2003 and December 2008. Tumors lacking expression of MLH1 and/or MSH2, as determined by immunohistochemistry, were classified as having deficient MMR (dMMR), whereas other tumors were classified as having proficient MMR (pMMR). Clinical risk (CR) factors were used to divide patients into high or standard CR groups. RESULTS: Of 860 patients, 14.7 % were dMMR, 42.4 % had ≥1 CR factors, and 85.8 % patients received adjuvant chemotherapy. MMR status did not affect disease-free survival (DFS; hazard ratio [HR] 1.191, p = 0.415) or overall survival (OS; HR 1.300, p = 0.344). Among CR factors, only pathologic T4 disease tended to associate with poor OS (HR 1.979, p = 0.071). Adjuvant chemotherapy was associated with better DFS (HR 0.393, p < 0.0001) in patients with pMMR tumors. However, in patients with dMMR tumors, adjuvant chemotherapy was not associated with DFS. CONCLUSIONS: MMR status did not affect DFS or OS in patients with stage II colon cancer. In patients treated with adjuvant chemotherapy, dMMR was not associated with DFS and OS. However, adjuvant chemotherapy was associated with improved DFS in pMMR patients.
BACKGROUND: Mismatch repair (MMR) status has been proposed, with some controversy, as a prognostic and predictive marker in stage II colon cancer. The aim of this study was to evaluate the association between MMR and survival in stage II colon cancer. METHODS: A total of 860 patients with curatively resected stage II colon cancer were selected for inclusion between January 2003 and December 2008. Tumors lacking expression of MLH1 and/or MSH2, as determined by immunohistochemistry, were classified as having deficient MMR (dMMR), whereas other tumors were classified as having proficient MMR (pMMR). Clinical risk (CR) factors were used to divide patients into high or standard CR groups. RESULTS: Of 860 patients, 14.7 % were dMMR, 42.4 % had ≥1 CR factors, and 85.8 % patients received adjuvant chemotherapy. MMR status did not affect disease-free survival (DFS; hazard ratio [HR] 1.191, p = 0.415) or overall survival (OS; HR 1.300, p = 0.344). Among CR factors, only pathologic T4 disease tended to associate with poor OS (HR 1.979, p = 0.071). Adjuvant chemotherapy was associated with better DFS (HR 0.393, p < 0.0001) in patients with pMMR tumors. However, in patients with dMMRtumors, adjuvant chemotherapy was not associated with DFS. CONCLUSIONS: MMR status did not affect DFS or OS in patients with stage II colon cancer. In patients treated with adjuvant chemotherapy, dMMR was not associated with DFS and OS. However, adjuvant chemotherapy was associated with improved DFS in pMMR patients.
Authors: Hee Jeong Cho; Jin Ho Baek; Dong Won Baek; Byung Woog Kang; Soo Jung Lee; Hye Jin Kim; Su Yeon Park; Jun Seok Park; Gyu Seog Choi; Jong Gwang Kim Journal: In Vivo Date: 2019 Nov-Dec Impact factor: 2.155
Authors: Gabrielle Jongeneel; Thomas Klausch; Felice N van Erning; Geraldine R Vink; Miriam Koopman; Cornelis J A Punt; Marjolein J E Greuter; Veerle M H Coupé Journal: Int J Cancer Date: 2019-08-31 Impact factor: 7.316
Authors: Elizabeth Alwers; Lina Jansen; Hendrik Bläker; Matthias Kloor; Katrin E Tagscherer; Wilfried Roth; Daniel Boakye; Esther Herpel; Carsten Grüllich; Jenny Chang-Claude; Hermann Brenner; Michael Hoffmeister Journal: Mol Oncol Date: 2020-01-07 Impact factor: 6.603